Litigation Details for Stegmann v. PetSmart LLC (N.D. Ill. 2022)
✉ Email this page to a colleague
Stegmann v. PetSmart LLC (N.D. Ill. 2022)
| Docket | ⤷ Sign Up | Date Filed | 2022-03-03 |
| Court | District Court, N.D. Illinois | Date Terminated | 2022-03-08 |
| Cause | 28:1332 Diversity-Petition for Removal | Assigned To | Gary Scott Feinerman |
| Jury Demand | None | Referred To | M. David Weisman |
| Patents | 8,231,876; 8,420,081; 8,663,945; 8,715,664; 8,883,156; 8,895,009; 8,906,372; 8,906,373; 8,906,646; 8,911,964; 8,916,153; 8,926,975; 8,999,337; 9,061,005; 9,062,106; 9,085,618; 9,085,619; 9,085,620; 9,090,688; 9,090,867; 9,096,666; 9,102,723; 9,150,645; 9,181,337; 9,181,572; 9,234,032; 9,266,949; 9,273,132; 9,284,370; 9,284,371; 9,290,568; 9,315,574; 9,328,165; 9,334,319; 9,346,879; 9,359,434; 9,499,614; 9,499,616; 9,505,834; 9,522,953; 9,550,826 | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Stegmann v. PetSmart LLC
The biologic drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .
Details for Stegmann v. PetSmart LLC (N.D. Ill. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-11-18 | 101 | other | proceeding involving the ’619 patent’s parent, U.S. Patent No. 8,420,081, lends further support to “water…indefinite, with terms in the ’792 patent being the most egregious. That patent, which AbbVie asserts covers…’s so-called “bufferless” patents, one of which, in violation of the Patent Dance confidentiality provisions… ARGUMENT The ’792 Patent The ’792 patent relates to methods for purifying … The ’619 and ’030 Patents The ’619 and ’030 patents share a common specification2 | External link to document |
| 2021-09-14 | 60 | answer to complaint | Protector Shroud 2. 8,231,876 Wan Purified…the ’081 patent, the ’975 patent, the ’973 patent, and the ’619 patent or any related patent because …the ’081 patent, the ’975 patent, the ’973 patent, and the ’619 patent due to Plaintiffs’ patent misuse…enforceable claim of the ’081 patent, the ’975 patent, the ’973 patent, and the ’619 patent, either literally or… claim of the ’081 patent, the ’975 patent, the ’973 patent, and the ’619 patent is invalid for failing | External link to document |
| 2021-09-20 | 63 | order | U.S. Patent No. 8,420,081 as one of the Ten Patents; and (3) the patent issuing from U.S. Patent Application…02889 to add (1) U.S. Patent No. 11,083,792; (2) the patent issuing from U.S. Patent Application No. 17/… related to the ten patents that will be subject to a first trial (“Ten Patents”)1, IT IS HEREBY ORDERED…9,187,559, 9,512,216, 11,083,792, and the patent issuing from U.S. Patent Application No. 17/137,201. Case…seek a preliminary injunction on any patents other than the Ten Patents. Plaintiffs shall not seek a preliminary | External link to document |
| 2021-11-14 | 99 | stipulation | Requests for Production related to U.S. Patent Nos. 6,805,686; 8,999,337; 9,067,992; 9,187,559; 9,512,216;…9,512,216; 11,083,792; and 11,167,030 (the patent issuing from U.S. Patent Application No. 17/137,201) (collectively…collectively, the “Remaining Patents”) by treating the term “Patents- in-Suit” as used in those Requests…served on August 25, 2021, to reflect all ten patents that will be tried in the August 2022 trial; and…Requests as including the Remaining Patents. AbbVie shall substantially complete this production on or before | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
